Eli Lilly and Incyte report positive data from Phase III RA-BEACON trial of baricitinib to treat rheumatoid arthritis

Eli Lilly and Company and Incyte Corporation announced that new data from RA-BEACON, a phase 3 study of baricitinib in the treatment of moderate-to-severe rheumatoid arthritis (RA), indicated baricitinib had demonstrated significant improvement in pa …
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news